HUYABIO International, LLC.

Privately held: no public share price · United States

Assets

(5 total)
5Total Assets
0Approved
2Phase 3 / Filed
3Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
HDACSmall molecule
Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma
HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma
Phase 3
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 2
SHP2Small molecule
Non-Small Cell Lung Cancer
Phase 1
SHP2Small molecule
Non-Small Cell Lung Cancer
Phase 1
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
GH21Phase 2Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2026-12-30 · NCT07318649 · CT.gov ↗
What to watch
2027 (2)
September 2027 (1)
GH21Phase 1/2Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Est. primary completion 2027-09-30 · NCT06435455 · CT.gov ↗
What to watch
December 2027 (1)
JMKX001899Phase 3NSCLC (Non-small Cell Lung Cancer)
Est. primary completion 2027-12-31 · NCT07242274 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
ChidamidePhase 3Colorectal Cancer
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
GH21Phase 1/2Advanced Solid Tumor Cancer
Est. primary completion 2029-10-30 · NCT07446725 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
ChidamidePhase 3Lymphoma, T-Cell, Peripheral
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗

Financial reports

No financial reports recorded.